Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CICC Raises BEONE MEDICINES's TP to HKD250; Rating Kept Outperform
Recommend 2 Positive 3 Negative 3 |
||||
|
||||
|
BEONE MEDICINES (06160.HK)'s 3Q25 results beat forecasts, according to a CICC report. The company's CDK4 first-line clinical trial is set to commence in 1H26. CICC kept an Outperform rating on BEONE MEDICINES and raised its target prices for the company's A-shares (688235.SH)/ H-shares/ US shares (ONC.US) by 3.2%/ 3.3%/ 3.7% to RMB320/ HKD250/ USD420. The report also highlighted a YoY increase of 41% in BEONE MEDICINES' operating revenue to USD1.41 billion. The company's non-GAAP net profit of USD125 million also exceeded market forecasts. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
